BridgeBio Pharma Shares Positive Long-Term Data from an Ongoing Phase 2 Study, which Support the Potential Use of Glycosylated Alpha-dystroglycan (⍺DG) Levels as a Surrogate Endpoint in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

- Early assessment of increased glycosylated ⍺DG levels at 3 months predicted subsequent ambulatory improvements at 9 months, supporting the use of glycosylated ⍺DG levels as a potential surrogate...

Related Keywords

Australia ,United Kingdom ,Charleston ,South Carolina ,United States ,Tamy Harper ,Douglas Sproule ,Vikram Bali ,Virginia Commonwealth University ,Ml Bio Solutions ,World Muscle Society ,Drug Administration ,Nasdaq ,Linkedin ,Bridgebio Pharma Inc ,Bio Pharma Inc ,Securities Exchange ,Twitter ,North Star Assessment ,Accelerated Approval ,Bio Pharma ,Annual Congress ,Limb Girdle Muscular Dystrophy Type ,Bridgebio Pharma ,Securities Act ,Securities Exchange Act ,Accelerated Approval Pathway ,Risk Factors ,Annual Report ,Bio Media Contact ,Markets ,